Cargando…

CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia

There is an unmet need for markers that can stratify different forms and subtypes of dementia. Because of similarities in clinical presentation, it can be difficult to distinguish between Alzheimer's disease (AD) and frontotemporal dementia (FTD). Using a multiplex targeted proteomic LC-MS/MS p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heywood, Wendy E., Hallqvist, Jenny, Heslegrave, Amanda J., Zetterberg, Henrik, Fenoglio, Chiara, Scarpini, Elio, Rohrer, Jonathan D., Galimberti, Daniela, Mills, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221294/ https://www.ncbi.nlm.nih.gov/pubmed/30292090 http://dx.doi.org/10.1016/j.neurobiolaging.2018.08.019

Ejemplares similares

Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer’s Disease and Frontotemporal Dementia(1)
por: Fenoglio, Chiara, et al.
Publicado: (2018)

Genetics of Frontotemporal Lobar Degeneration
por: Galimberti, Daniela, et al.
Publicado: (2012)

Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
por: Heywood, Wendy E., et al.
Publicado: (2016)

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
por: Heywood, Wendy E., et al.
Publicado: (2015)

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
por: Clarke, Mica T. M., et al.
Publicado: (2019)

The Role of the Innate Immune System in Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Eye on Microglia
por: Ridolfi, Elisa, et al.
Publicado: (2013)

Circulating Non-Coding RNA Levels Are Altered in Autosomal Dominant Frontotemporal Dementia
por: Fenoglio, Chiara, et al.
Publicado: (2022)

Profiling of Ubiquitination Pathway Genes in Peripheral Cells from Patients with Frontotemporal Dementia due to C9ORF72 and GRN Mutations
por: Serpente, Maria, et al.
Publicado: (2015)

Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients
por: Bossù, Paola, et al.
Publicado: (2011)

An Emerging Role for Long Non-Coding RNA Dysregulation in Neurological Disorders
por: Fenoglio, Chiara, et al.
Publicado: (2013)

MicroRNAs as Active Players in the Pathogenesis of Multiple Sclerosis
por: Fenoglio, Chiara, et al.
Publicado: (2012)

CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia
por: Woollacott, Ione O. C., et al.
Publicado: (2022)

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2023)

Plasma tau is increased in frontotemporal dementia
por: Foiani, Martha S, et al.
Publicado: (2018)

Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery
por: Buccellato, Francesca Romana, et al.
Publicado: (2021)

Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools
por: D’Anca, Marianna, et al.
Publicado: (2021)

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study
por: van der Ende, Emma L., et al.
Publicado: (2022)

Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology
por: Scarioni, Marta, et al.
Publicado: (2020)

Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage
por: Pietroboni, Anna M., et al.
Publicado: (2022)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
por: Alawode, Deborah O. T., et al.
Publicado: (2022)

Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
por: D’Anca, Marianna, et al.
Publicado: (2019)

Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation
por: Rosadas, Carolina, et al.
Publicado: (2021)

Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis
por: Wilson, Katherine M, et al.
Publicado: (2022)

‘The long tail of Covid-19’ - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients
por: Doykov, Ivan, et al.
Publicado: (2021)

Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales
por: Fumagalli, Giorgio G., et al.
Publicado: (2018)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures
por: Falgàs, Neus, et al.
Publicado: (2020)

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
por: Woollacott, Ione O. C., et al.
Publicado: (2018)

IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment
por: Saresella, Marina, et al.
Publicado: (2020)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Increased orexin A concentrations in cerebrospinal fluid of patients with behavioural variant frontotemporal dementia
por: Roveta, Fausto, et al.
Publicado: (2021)

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease
por: Arcaro, Marina, et al.
Publicado: (2022)

Case Report: Reduced CSF Orexin Levels in a Patient With Sepsis
por: Ogawa, Yasuhiro, et al.
Publicado: (2021)

Endo‐lysosomal protein concentrations in CSF from patients with frontotemporal dementia caused by CHMP2B mutation
por: Toft, Anders, et al.
Publicado: (2023)

Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
por: van der Ende, Emma L, et al.
Publicado: (2020)

Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis
por: Padovani, Alessandro, et al.
Publicado: (2022)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study
por: Bergström, Sofia, et al.
Publicado: (2021)

Disease-modifying drugs in Alzheimer’s disease
por: Ghezzi, Laura, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s33e0cms2gg5ikrdpnsjsh0fvp